Recent data marking 4.5 years of use showed that more than 90% of patients taking Gleevec continued to survive and were free from progressing to advanced disease. A five-year update
from the IRIS study (International Randomized Interferon versus STI571), the largest clinical trial to date for newly diagnosed adult patients with Ph+ CML, will be presented at the American Society of Clinical Oncology meeting on June 3. Before Gleevec was available, about 50% of patients progressed to the more advanced stages of Ph+ CML after only three to five years, and survival was generally short for those patients.
Posted by Rob to CML Newswire: Medical And Technical News On Chronic Myelogenous Leukemia at 5/12/2006 02:31:00 AM
--
Powered by NewOrleansEmail.Com http://neworleansemail.com
--~--~---------~--~----~------------~-------~--~----~
[CMLHope]
A support group of http://cmlhope.com
-------------------------------------------------
You received this message because you are subscribed to the Google Groups "CMLHope" group.
To post to this group, send email to [email protected]
To unsubscribe from this group, send email to [EMAIL PROTECTED]
For more options, visit this group at http://groups.google.com/group/CMLHope
-~----------~----~----~----~------~----~------~--~---
